FSSAI initiates three adjudication cases against Nestlé India over infant nutrition claims

India’s food regulator has initiated three adjudication cases against Nestlé India concerning claims around HMOs and digestibility in infant nutrition products. The development matters because milk products and nutrition contribute about one-third of the company’s sales.

— Source publishedMon, 21 Sept, 2026, 06:30 IST·First seen Mon, 21 Sept, 2026, 08:37 IST·Source The Hindu BusinessLine

What happened

FSSAI has initiated regulatory action against Nestle India over claims concerning HMOs and digestibility in infant nutrition products, with three adjudication

Key facts

  • Three separate adjudication cases
  • Milk products and nutrition contribute one-third of sales

Why this matters

Corporate development teams should factor stricter Indian substantiation standards and possible compliance liabilities into any nutrition-category partnership, acquisition or portfolio assessment.

What to watch

  • FSSAI adjudication notices specifying alleged violations, affected SKUs, and proposed penalties or corrective actions.
  • Any interim direction to stop advertising, alter labels, suspend sales, or recall products.
  • Nestlé India disclosures on provisions, legal risk, sales impact, or changes to infant-nutrition marketing.
  • Evidence of similar FSSAI actions against competing infant-formula or pediatric-nutrition brands.
  • Retailer, pharmacy, hospital, or e-commerce changes to product availability, search visibility, or promotional placement.
  • Consumer and pediatrician sentiment, especially if the matter gains mainstream media traction.
  • Conduct a claim-by-claim legal, scientific, and label audit across infant nutrition products, including e-commerce listings and healthcare-professional communications.
  • Prepare revised packaging, point-of-sale materials, and digital copy that can be deployed quickly if corrective directions are issued.
  • Increase engagement with pediatricians, hospitals, distributors, and retailers to preserve trust and avoid channel-level delisting or inventory interruptions.
  • Build contingency plans for reformulation, SKU substitution, and inventory withdrawal in affected product lines.
  • Review adjacent nutrition and milk-product claims proactively, as FSSAI may extend scrutiny beyond the three cases.

Also reported by